Exenatide improves cardiovascular risk factors in obese patients with type 2 diabetes mellitus: a prospective study.

CONCLUSION: This study showed improvement in lipid profile and hsCRP levels with exenatide treatment. We also showed decrease in both visceral fat volume and subcutaneous fat thickness. We demonstrated significant decrease in liver enzymes with significant decrease in liver diameter. These findings supports the use of exenatide in patients with NAFLD and T2DM. Additionally this study showed that twice daily exenatide treatment reduces CIMT in obese T2DM patients. PMID: 32892547 [PubMed - as supplied by publisher]
Source: Turkish Journal of Medical Sciences - Category: General Medicine Tags: Turk J Med Sci Source Type: research